Ultragenyx Pharmaceutical Inc. Collaboration Agreements
18 Contracts & Agreements
- Amendment No. 13 to Collaboration and License Agreement, effective as of May 16, 2023, between Ultragenyx Pharmaceutical Inc. and Kyowa Kirin, Co., Ltd (Filed With SEC on August 4, 2023)
- Amendment No. 12 to Collaboration and License Agreement, effective as of September 29, 2022, between Ultragenyx Pharmaceutical Inc. and Kyowa Kirin Co., Ltd (Filed With SEC on November 3, 2022)
- Amendment No. 11 to Collaboration and License Agreement, effective as of December 17, 2021 between Ultragenyx Pharmaceutical Inc. and Kyowa Kirin Co., Ltd (Filed With SEC on February 15, 2022)
- Amendment 10 to Collaboration and License Agreement effective as of April 1, 2020 between Ultragenyx Pharmaceutical Inc. and Kyowa Kirin Co., Ltd (Filed With SEC on May 7, 2020)
- Amendment No. 9 to Collaboration and License Agreement, effective December 23, 2019, between Ultragenyx Pharmaceutical Inc. and Kyowa Kirin Co., Ltd (Filed With SEC on February 14, 2020)
- Amended and Restated Collaboration and License Agreement, dated June 3, 2019, between Ultragenyx Pharmaceutical Inc. and Bayer Healthcare LLC (Filed With SEC on August 2, 2019)
- Amendment No. 8 to Collaboration and License Agreement, effective as of July 4, 2019, between Ultragenyx Pharmaceutical Inc. and Kyowa Kirin Co., Ltd. (formerly, Kyowa Hakko Kirin... (Filed With SEC on August 2, 2019)
- Amendment No. 7 to Collaboration and License Agreement, entered into as of December 5, 2018, between Ultragenyx Pharmaceutical Inc. and Kyowa Hakko Kirin Co., Ltd (Filed With SEC on May 7, 2019)
- Amendment No. 6 to Collaboration and License Agreement, effective as of February 1, 2019, between Ultragenyx Pharmaceutical Inc. and Kyowa Hakko Kirin Co., Ltd (Filed With SEC on May 7, 2019)
- Amendment No. 5 to Collaboration and License Agreement, effective as of April 30, 2018, between Ultragenyx Pharmaceutical Inc. and Kyowa Hakko Kirin Co., Ltd (Filed With SEC on August 3, 2018)
- Amendment No. 4 to Collaboration and License Agreement, effective as of January 29, 2018, between Ultragenyx Pharmaceutical Inc. and Kyowa Hakko Kirin Co., Ltd (Filed With SEC on February 21, 2018)
- Amendment No. 3 to Collaboration and License Agreement, effective September 29, 2017, between Ultragenyx Pharmaceutical Inc. and Kyowa Hakko Kirin Co., Ltd (Filed With SEC on February 21, 2018)
- Amendment No. 2 to Collaboration and License Agreement, effective as of November 28, 2016, between Ultragenyx Pharmaceutical Inc. and Kyowa Hakko Kirin Co., Ltd (Filed With SEC on February 21, 2018)
- AMENDMENT NO. 1 TO COLLABORATION AND LICENSE AGREEMENT (Filed With SEC on November 10, 2015)
- COLLABORATION AND LICENSE AGREEMENT BETWEEN NOBELPHARMA CO.,LTD. AND ULTRAGENYX PHARMACEUTICALS, INC (Filed With SEC on December 23, 2013)
- COLLABORATION AND LICENSE AGREEMENT by and between KYOWAHAKKO KIRIN CO., LTD. and ULTRAGENYX PHARMACEUTICAL INC. Dated August 29, 2013 (Filed With SEC on December 23, 2013)
- COLLABORATION AND LICENSE AGREEMENT BETWEEN NOBELPHARMA CO.,LTD. AND ULTRAGENYX PHARMACEUTICALS, INC (Filed With SEC on November 8, 2013)
- COLLABORATION AND LICENSE AGREEMENT by and between KYOWAHAKKO KIRIN CO., LTD. and ULTRAGENYX PHARMACEUTICAL INC. Dated August 29, 2013 (Filed With SEC on November 8, 2013)
